The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study (Q47598171)

4 February 2018

title

The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study (English)

1 reference

4 February 2018

author name string

Feyler S

1

1 reference

4 February 2018

Prince HM

2

1 reference

4 February 2018

Pearce R

3

1 reference

4 February 2018

Towlson K

4

1 reference

4 February 2018

Nivison-Smith I

5

1 reference

4 February 2018

Schey S

6

1 reference

4 February 2018

Gibson J

7

1 reference

4 February 2018

Patton N

8

1 reference

4 February 2018

Bradstock K

9

1 reference

4 February 2018

Marks DI

10

1 reference

4 February 2018

Cook G

11

1 reference

4 February 2018

language of work or name

English

0 references

publication date

25 June 2007

1 reference

4 February 2018

Bone Marrow Transplantation

published in

1 reference

4 February 2018

volume

40

1 reference

4 February 2018

issue

5

1 reference

4 February 2018

page(s)

443-450

1 reference

4 February 2018

Clinical significance of immunophenotype in diffuse aggressive non-Hodgkin's lymphoma

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705752

7 January 2021

Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d'Etude des Lymphomes Agressives).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705752

7 January 2021

High-dose therapy and autologous stem cell transplant does not result in long-term disease-free survival in patients with recurrent chemotherapy-sensitive ALK-negative anaplastic large-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705752

7 January 2021

Impact of high-dose chemotherapy on peripheral T-cell lymphomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705752

7 January 2021

Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705752

7 January 2021

Histology impacts the outcome of peripheral T-cell lymphomas after high dose chemotherapy and stem cell transplant

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705752

7 January 2021

Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705752

7 January 2021

Allogeneic bone marrow transplantation in patients who relapse after autologous transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705752

7 January 2021

Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705752

7 January 2021

High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705752

7 January 2021

Autologous stem cell transplantation in adult patients with peripheral T-cell lymphoma: a nation-wide survey.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705752

7 January 2021

High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705752

7 January 2021

Myeloablative radiochemotherapy followed by autologous peripheral blood stem cell transplantation as first-line therapy in peripheral T-cell lymphomas: first results of a prospective multicenter study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705752

7 January 2021

Autologous stem cell transplantation for T and null cell CD30-positive anaplastic large cell lymphoma: analysis of 64 adult and paediatric cases reported to the European Group for Blood and Marrow Transplantation (EBMT)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705752

7 January 2021

The role of allogeneic transplantation in non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705752

7 January 2021

Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705752

7 January 2021

Treatment of peripheral T-cell lymphomas (PTCL) with high-dose chemotherapy and autologous or allogeneic hematopoietic transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705752

7 January 2021

Allogeneic bone marrow transplantation in aggressive non-Hodgkin's lymphoma (excluding Burkitt and lymphoblastic lymphoma): a series of 73 patients from the SFGM database

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705752

7 January 2021

Graft-versus-lymphoma effect in refractory cutaneous T-cell lymphoma after reduced-intensity HLA-matched sibling allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705752

7 January 2021

Donor lymphocyte infusions can result in sustained remissions in patients with residual or relapsed lymphoid malignancy following allogeneic haemopoietic stem cell transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705752

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1705752

1 reference

4 February 2018

release_jpk6v4c7z5chtpzsmlbodn5luy

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/jpk6v4c7z5chtpzsmlbodn5luy

24 November 2022

mapped directly with Wikidata item

1 reference

4 February 2018